Pharmacology Student Publications 2009-2010

 

  • Brady DC, Alan JK, Madigan JP, Fanning AS, Cox AD.  The transforming Rho family GTPase Wrch-1 disrupts epithelial cell tight junctions and epithelial morphogenesis. Mol Cell Biol. 29:1035-1049, 2009.
  • González-Pérez V, Reiner DJ, Alan JK, Mitchell C, Edwards LJ, Khazak V, Der CJ, and Cox AD.  Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C elegans and mammalian cells.  J Mol Signal. In press, 2010.
  • Brady DC, Alan JK, and Cox AD.  Rho GTPases in regulation of cancer cell motility, invasion, and microenvironment. Thomas-Tikhonenko, A (ed.), Cancer Genome and the Tumor Microenvironment, 2009.
  • Bauman J, Jearawiriyapaisarn N, and Kole R.  Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides, 19:1-14, 2009.
  • Juliano R, Bauman J, Kang H, and Ming X.  Biological barriers of therapy with antisense and siRNA oligonucleotides. Mol Pharm. 6:686-695.
  • Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, and Johnson GL.  J. Biol. Chem. 285:11760-11764, 2010.
  • Abell AN, Granger DA, Johnson NL, Vincent-Jordan N, Dibble CF, and Johnson GL. Trophoblast stem cell maintenance by fibroblast growth factor 4 requires MEKK4 activation of Jun N-terminal kinase. Mol Cell Biol. 29:2748-2761, 2009.
  • Li C, Hirsch M, DiPrimio N, Asokan A, Goudy K, Tisch R, and Samulski RJ.  Cytotoxic T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.  J Virol. 83:6817-6824, 2009.
  • Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, Diprimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, and Samuski RJ.  Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle.  Nature Biotechonol.  28:79-82, 2010.
  • Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, and Nicholas RA.  Genetics of chromosomally mediated intermediate resistance to ceftiaxone and cefixime in Neisseria gonorrhoeae.  Antimicrob Agents Chemother. 53:3744-3751, 2009.
  • Farrell M and Roth BL.  Allosteric antipsychotics: m4 muscarinic potentiators as novel treatments for schizophrenia.  Neuropsychopharmacol.35:851-852, 2009.
  • Abbas AI, Urban DJ, Jensen NH, Farrell MS, Kroeze WK, Mieczkowski P, Wang Z, and Roth BL.  Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method.  Nucleic Acids Res. 2010 Feb 25. [Epub ahead of print]
  • Fricks, IP, Carter, RL, Lazarowski, ER, and Harden TK.  Gi-dependent cell signaling response of the human P2Y14 receptor in model cell systems.  J Pharmacol Exp Ther. 330:162-168, 2009.
  • Ko H, Das A, Carter RL, Fricks IP, Zhou Y, Ivanov AA, Harden TK, and Jacobson KA.  Molecular recognition in the P2Y14 receptor. Biorg Med Chem. 17:5298-5311, 2009.
  • Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, Das A, Jacobson KA, Lazarowski ER, and Harden TK.  Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor.  Mol. Pharmacol. 76:1341-1348, 2009.
  • Guerrier S, Coutinho-Budd J, Sassa T, Gresset A, Jordan NV, Chen K, Jin WL, Frost A, and Polleux F.  The F-BAR domain of SrGAP2 induces membrane protrusions required for neuronal migration and morphogenesis. Cell 138:990-1004, 2009.
  • Johnson JS and Samulski RJ.  Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus.  J Virol. 83:2632-2644, 2008.
  • Li W, Zhang L, Johnson JS, Zhijian W, Grieger JC, Ping-Jie X, Drouin LM, Agbandje-McKenna M, Pickles RJ, and Samulski RJ.  Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.  Mol Ther. 17:2067-2077, 2009.
  • Kelm MK, Weinberg RJ, Criswell HE, and Breese GR.  The PLC/IP3 pathway is required for ethanol-enhanced GABA release.  Neuropharmacol. 58:1179-86, 2010.
  • Lambert NA, Johnston CA, Cappell SD, Kuravi S, Kimple AJ, Willard FS, and Siderovski DP.  Regulators of G protein signaling accelerate GPCR signaling kinetics and govern sensitivity solely by accelerating GTPase activity.  Proc Natl Acad Sci USA. 107:7066-7071, 2010.
  • Nakamura K, Kimple AJ, Siderovski DP, and Johnson GL.  PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation.  J Biol Chem. 285:2077-89, 2010.
  • Preininger A, Funk M, Meier S, Oldham W, Johnston C, Adhikary S, Kimple A, Siderovski D, Hamm H, and Iverson T.  Helix dipole movement and conformational variability contribute to allosteric GDP release in Gi subunits. Biochemistry 48: 2630-2642, 2009.
  • Willard FS, Willard MD, Kimple AJ, Soundararajan M, Oestreich EA, Li X, Sowa NA, Kimple RJ, Doyle DA, Der CJ, Zylka MJ, Snider, WD, and Siderovski DP.  Regulator of G-protein signaling 14 (RGS14) is a selective H-Ras effector. PLoS ONE. 4: e4884, 2009.
  • Kimple AJ, Soundararajan M, Hutsell SQ, Roos AK, Urban DJ, Setola V, Temple BR, Roth BL, Knapp S, Willard FS, and Siderovski DP.  Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2). J. Biol. Chem. 284: 19402-19411.
  • Kimple AJ, Zielinski T, Hutsell SQ, Koeff MD, Siderovski DP, and Lowery RG.  Two Gαi1 rate-modifying mutations act in concert to allow receptor independent, steady-state measurements of RGS protein activity.  J.Biol. Screening 14:1195-1206, 2009.
  • Torres MP, Lee MJ, Ding F, Purbeck C, Kuhlman B, Dokholyan NV, and Dohlman HG.  G protein mono-ubiqutination by Rsp5 ubiquitin ligase.  J Biol Chem. 284:8940-8950, 2009.
  • Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, and McCown TJ.  Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier.  Molecular Therapy 18:570-578, 2009.
  • Kita JM, Kile BM, Parker LE, and Wightman RM.  In vivo measurement of somatodendritic release of dopamine in the ventral tegmental area.  Synapse 63:951-960, 2009.
  • Proctor A, Yang S, Kottegoda S, Brenner M, Phillips RM, Sims CE, and Albritton NL.  Cell signaling studied at the single cell level.  In Chemical Cytometry;  ed. By Chang Lu; WILEY-VCH Verlag GmbH & Co., Weinheim, pp. 31-54, 2009.
  • Ricks TK and Trejo J.  Phosphorylation differentially regulates protease-activated receptor 2 desensitization and internalization.  J.Biol.Chem. 284:34444-34457, 2009
  • Dong, S, Rogan SC, and Roth BL.  Directed molecular evolution of DREADDs:  a generic approach to creating next-generation RASSLs. Nature Protocols 5:561-573, 2010.
  • Alexander GM, Rogan SC, Abbas Al, Armbruster BN, Pei Y, Allen JA, Nonnerman RJ, Hartmann J, Moy SS, Nicolelis MA, McNamara JO, and Roth BL.  Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron. 63:27-39, 2009.
  • Huang, XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, and Roth BL.  Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists:  implications for drug safety assessment.  Mol Pharmacol. 76:710-722, 2009.
  • Pei Y, Rogan SC, Yan F, and Roth BL.  Engineered GPCRs as tools to modulate signal transduction.  Physiology 23:313-21, 2009.
  • Montes M, Zhang X, Berthelot L, Laplaud DA, Brouard S, Jin J, Rogan SC, Armao D, Jewells V, Soulillou JP, and Markovic-Plese S.  Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells.  Clin Immunol. 130:133-144, 2009.
  • Evelyn CR, Ferng T, Rojas RJ, Larsen MJ, Sondek J, Neubig RR.  High-throughput screening for small molecule inhibitors of LARG-stimulated RhoA nucleotide binding via a novel fluorescence polarization assay.  J Biomol Screen. 14:161-172, 2009.
  • Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, and Schoenfisch MH.  Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm. in press, 2010.
  • Machacek M, Hodgson L, Welch CM, Elliott H, Pertz O, Shen F, Abell A, Johnson GL, Hahn KM, and Danuser G.  Coordination of Rho GTPase activities during cell protrusion.  Nature 461:99–103, 2009.
  • Koivusalo M, Welch CM, Hayashi H, Scott CC, Kim M, Alexander T, Touret N, Hahn KM, and Grinstein S.  Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signalling. J. Cell Biol., in press, 2010.
  • Samson T, Welch C, Monaghan-Benson E, Hahn KM, and Burridge K.  Endogenous RhoG is rapidly activated after epidermal growth factor stimulation through multiple guanine nucleotide exchange factors.  Mol Biol Cell. 21:1629-42, 2010.
  • Das A, Zhou Y, Ivanov AA, Carter RL, Harden TK, and Jacobson KA.  Enhanced potency of nucleotide-dendrimer conjugates as agonists of the P2Y14 receptor: multivalent effect in G protein-coupled receptor recognition.  Bioconjug Chem. [Epub ahead of print]
  • Zimmerman EI, Huang M, Leisewitz AV, Wang Y, Yang J, and Graves LM.  Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human leukemia CCRF-CEM cells.  FEBS Lett. 583:425-429, 2009.